| Literature DB >> 25380351 |
Yi-Shuan Sheen1, Yi-Hua Liao1, Ming-Hsien Lin2, Chia-Ying Chu3, Bing-Ying Ho1, Meng-Chen Hsieh1, Pin-Chun Chen1, Shih-Ting Cha4, Yung-Ming Jeng5, Cheng-Chi Chang6, Hsien-Ching Chiu1, Shiou-Hwa Jee1, Min-Liang Kuo4, Chia-Yu Chu7.
Abstract
IGF II mRNA-binding protein 3 (IMP-3) has been reported to be a marker of melanoma progression. However, the mechanisms by which it impacts melanoma are incompletely understood. In this study, we investigate the clinical significance of IMP-3 in melanoma progression and also its underlying mechanisms. We found that IMP-3 expression was much higher in advanced-stage/metastatic melanomas and that it was associated with a poor prognosis (P=0.001). Univariate analysis showed that IMP-3 expression was associated with stage III/IV melanomas (odds ratio=5.40, P=0.031) and the acral lentiginous subtype (odds ratio=3.93, P=0.0034). MeWo cells with overexpression of IMP-3 showed enhanced proliferation and migration and significantly increased tumorigenesis and metastatic ability in nude mice. We further demonstrated that IMP-3 could bind and enhance the stability of the mRNA of high mobility group AT-hook 2 (HMGA2). It was also confirmed that IMP-3 had an important role in melanoma invasion and metastasis through regulating HMGA2 mRNA expression. IMP-3 expression was positively correlated with HMGA2 expression in melanoma cells and also in melanoma tissues. Our results show that IMP-3 expression is a strong prognostic factor for melanoma, especially acral lentiginous melanoma.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25380351 DOI: 10.1038/jid.2014.480
Source DB: PubMed Journal: J Invest Dermatol ISSN: 0022-202X Impact factor: 8.551